BOLD-100 MoA Research to Be Presented at the AACR Annual Meeting
- Friday, April 9, 2021, 7:12
- PR Newswire
- Add a comment
PHILADELPHIA, April 9, 2021 /PRNewswire/ — Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, a first-in-class anti-cancer agent, announced that Sandra Van Schaeybroeck, PhD (Queen’s University Belfast) will be presenting research supporting BOLD-100 as a…
About the Author
admin has written 21729 stories on this site.